Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.
本文披露了β-连接蛋白/B细胞淋巴瘤9相互作用的
抑制剂。这些
抑制剂对β-连接蛋白/B细胞淋巴瘤9的选择性高于β-连接蛋白/E-
钙粘蛋白P
PI相互作用。还披露了使用这些披露的化合物来治疗癌症的方法。